Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Adenocarcinoma × tislelizumab × Clear all

Phase

Status

Terminated 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 8 Esophageal Squamous Cell Carcinoma 6 Carcinoma, Non-Small-Cell Lung 6 Stomach Neoplasms 4 Neoplasm Metastasis 4 Head and Neck Neoplasms 4 Recurrence 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Advanced Solid Tumors 3 Advanced Solid Tumor 3 Squamous Cell Carcinoma of Head and Neck 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Ovarian Neoplasms 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 NSCLC 1 Multiple Pulmonary Nodules 1 Mid-low Rectal Cancer 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1

Interventions

Gemcitabine 26 Fluorouracil 23 Oxaliplatin 19 Cisplatin 18 Leucovorin 15 Bevacizumab 14 Paclitaxel 12 130-nm albumin-bound paclitaxel 12 Capecitabine 11 Docetaxel 10 Albumin-Bound Paclitaxel 10 Irinotecan 9 Carboplatin 9 pembrolizumab 6 Radiotherapy 6 Pemetrexed 6 Nivolumab 6 Cyclophosphamide 6 Ramucirumab 5 Erlotinib Hydrochloride 5 Trastuzumab 4 Everolimus 4 Cetuximab 4 vandetanib 3 trastuzumab deruxtecan 3 sargramostim 3 folfirinox 3 Sorafenib 3 Ipilimumab 3 Gefitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06238752 2024-02-02

RENMIN-213

Renmin Hospital of Wuhan University

Phase 2 Completed

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡